Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis
暂无分享,去创建一个
C. Benna | A. Ferlin | G. Grande | P. Del Fiore | A. Di Nisio | M. S. Rocca | I. Cosci | S. Mocellin
[1] R. Flyckt,et al. Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology. , 2022, JCO oncology practice.
[2] F. Mancini,et al. The Role of Testosterone in Spermatogenesis: Lessons From Proteome Profiling of Human Spermatozoa in Testosterone Deficiency , 2022, Frontiers in Endocrinology.
[3] D. Schadendorf,et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Broniatowska,et al. Molecular Proof of a Clinical Concept: Expression of Estrogen Alpha-, Beta-Receptors and G Protein-Coupled Estrogen Receptor 1 (GPER) in Histologically Assessed Common Nevi, Dysplastic Nevi and Melanomas , 2021, Medicina.
[5] T. Falcone,et al. Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction. , 2021, Reproductive biomedicine online.
[6] O. Dekkers,et al. Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study , 2021, Cancers.
[7] Z. Apalla,et al. Effect of estrogen in malignant melanoma , 2021, Journal of cosmetic dermatology.
[8] A. Enk,et al. Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. , 2021, European journal of cancer.
[9] T. Key,et al. Prospective analyses of testosterone and sex hormone‐binding globulin with the risk of 19 types of cancer in men and postmenopausal women in UK Biobank , 2021, International journal of cancer.
[10] S. Mott,et al. Testosterone deficiency in men receiving immunotherapy for malignant melanoma , 2021, Oncotarget.
[11] B. Özdemir. Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology , 2021, Journal for ImmunoTherapy of Cancer.
[12] A. Geller,et al. Epidemiology of Melanoma. , 2021, Hematology/oncology clinics of North America.
[13] D. Fisher,et al. Biology of Melanoma. , 2021, Hematology/oncology clinics of North America.
[14] Ran Mo,et al. Sex-specific survival benefit in early skin melanoma based on 8th AJCC edition: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database , 2020, Annals of translational medicine.
[15] M. Rabinowitz,et al. Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma , 2020, Urology case reports.
[16] J. Foskett,et al. ZIP9 Is a Druggable Determinant of Sex Differences in Melanoma , 2020, Cancer Research.
[17] P. Lambert,et al. Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study , 2020, British journal of cancer.
[18] M. Szczyrek,et al. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review , 2020, Cancers.
[19] S. Loges,et al. Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer , 2020, Frontiers in Immunology.
[20] L. Ginaldi,et al. Sex and Gender Influences on Cancer Immunotherapy Response , 2020, Biomedicines.
[21] L. C. Spolidorio,et al. Testosterone Increases Fibroblast Proliferation in vitro Through Androgen and Estrogen Receptor Activation. , 2020, Journal of the International Academy of Periodontology.
[22] J. Hooper,et al. Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma. , 2020, JAMA oncology.
[23] X. Bai,et al. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase , 2020, Endocrine.
[24] G. Ciriello,et al. Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis , 2020, bioRxiv.
[25] J. Welborn,et al. Germline mutations predisposing to melanoma , 2020, Journal of cutaneous pathology.
[26] J. Wernberg,et al. Epidemiology and Risk Factors of Melanoma. , 2020, The Surgical clinics of North America.
[27] Franck Rouby,et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database , 2019, Scientific Reports.
[28] J. D'haese,et al. Advances in cancer immunotherapy 2019 – latest trends , 2019, Journal of Experimental & Clinical Cancer Research.
[29] Matthew R. Schwartz,et al. Sex Differences in Melanoma , 2019, Current Epidemiology Reports.
[30] K. Goldberg,et al. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Matthew J. Frigault,et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[32] I. Camacho-Arroyo,et al. Testosterone Promotes Glioblastoma Cell Proliferation, Migration, and Invasion Through Androgen Receptor Activation , 2019, Front. Endocrinol..
[33] F. Cools,et al. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors , 2018, Hormone and Metabolic Research.
[34] K. Hargadon,et al. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. , 2018, International immunopharmacology.
[35] A. Goldhirsch,et al. Different effectiveness of anticancer immunotherapy in men and women relies on sex-dimorphism of the immune system , 2018, Oncotarget.
[36] J. Wolchok,et al. 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. , 2018 .
[37] R. Gelber,et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. , 2018, The Lancet. Oncology.
[38] D. Bedognetti,et al. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives , 2018, Front. Immunol..
[39] Demetrios A. Spandidos,et al. Cutaneous melanoma: From pathogenesis to therapy (Review) , 2018, International journal of oncology.
[40] Matthew D. Hellmann,et al. Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.
[41] P. Dickman,et al. Sex differences in cancer risk and survival: A Swedish cohort study. , 2017, European journal of cancer.
[42] S. Ghafouri-Fard,et al. Melanoma: a prototype of cancer-testis antigen-expressing malignancies. , 2017, Immunotherapy.
[43] D. Schadendorf,et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.
[44] Huirong Shi,et al. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. , 2017, Oncotarget.
[45] R. Sullivan,et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] S. Klein,et al. Sex differences in immune responses , 2016, Nature Reviews Immunology.
[47] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[48] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[49] I. Melero,et al. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. , 2015, Seminars in oncology.
[50] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[51] T. Jones,et al. Testosterone and obesity , 2015, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[52] P. Baade,et al. Melanoma survival is superior in females across all tumour stages but is influenced by age , 2015, Archives of Dermatological Research.
[53] F. Cappuzzo,et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.
[54] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[55] M. Sznol. Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy , 2014, Cancer journal.
[56] Shutao Zhao,et al. Testicular defense systems: immune privilege and innate immunity , 2014, Cellular and Molecular Immunology.
[57] J. Wolchok,et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. , 2014, Endocrine-related cancer.
[58] P. Fox,et al. Immunohistochemical Expression of Hormone Receptors in Melanoma of Pregnant Women, Nonpregnant Women, and Men , 2014, The American Journal of dermatopathology.
[59] C. Zouboulis,et al. Steroidogenesis in the skin: Implications for local immune functions , 2013, The Journal of Steroid Biochemistry and Molecular Biology.
[60] D. Fisher,et al. Disproportionate burden of melanoma mortality in young U.S. men: the possible role of biology and behavior. , 2013, JAMA dermatology.
[61] S. Swetter,et al. Melanoma survival disadvantage in young, non-Hispanic white males compared with females. , 2013, JAMA dermatology.
[62] R. Simó,et al. Testosterone induces cell proliferation and cell cycle gene overexpression in human visceral preadipocytes. , 2013, American journal of physiology. Cell physiology.
[63] V. de Giorgi,et al. Oestrogen receptor beta and melanoma: a comparative study , 2013, The British journal of dermatology.
[64] Daishu Han,et al. Structural, cellular and molecular aspects of immune privilege in the testis , 2012, Front. Immun..
[65] S. Oertelt-Prigione. The influence of sex and gender on the immune response. , 2012, Autoimmunity reviews.
[66] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[67] J. Coebergh,et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. , 2011, The Journal of investigative dermatology.
[68] J. M. Kumar,et al. 17β-estradiol-linked nitro-L-arginine as simultaneous inducer of apoptosis in melanoma and tumor-angiogenic vascular endothelial cells. , 2011, Molecular pharmaceutics.
[69] Suzanne R. Thibodeaux,et al. B7-H1–Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses , 2010, The Journal of Immunology.
[70] A. Vandenbark,et al. Membrane Estrogen Receptor Regulates Experimental Autoimmune Encephalomyelitis through Up-regulation of Programmed Death 11 , 2009, The Journal of Immunology.
[71] A. Bokov,et al. The Effect Of Gonadectomy And Estradiol On Sensitivity To Oxidative Stress , 2009, Endocrine Research.
[72] J. Grant-Kels,et al. Estrogen receptor expression in cutaneous melanoma. , 2009, Archives of dermatology.
[73] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[74] P. Matarrese,et al. Redox state and gender differences in vascular smooth muscle cells , 2008, FEBS letters.
[75] A. Castrucci,et al. Photoperiod and testosterone modulate growth and melanogenesis of s91 murine melanoma. , 2008, Medicinal chemistry (Shariqah (United Arab Emirates)).
[76] A. Vandenbark,et al. Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). , 2007, International immunology.
[77] Johan Hartman,et al. Estrogen Receptor β Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts , 2006 .
[78] A. Bleyer,et al. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. , 2006 .
[79] J. Gustafsson,et al. Estrogen receptors alfa (ERα) and beta (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11 , 2005, Oncogene.
[80] J. Tímár,et al. In vitro and in vivo antitumor effect of 2‐methoxyestradiol on human melanoma , 2004, International journal of cancer.
[81] T. Slaga,et al. Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2‐methoxyoestradiol: therapeutic implications? , 2003, Melanoma research.
[82] J. Sastre,et al. Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. , 2003, Free radical biology & medicine.
[83] M. Capurro,et al. Androgen receptors in human melanoma cell lines IIB-MEL-LES and IIB-MEL-IAN and in human melanoma metastases , 2002, Melanoma research.
[84] S. Watanabe,et al. 17beta-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. , 2001, The Journal of investigative dermatology.
[85] J. Gustafsson,et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. , 2001, Cancer research.
[86] J. Gustafsson,et al. Estrogen receptor β in the breast: role in estrogen responsiveness and development of breast cancer , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[87] P. Lorigan,et al. Investigation of female survival benefit in metastatic melanoma , 1999, British Journal of Cancer.
[88] M. Capurro,et al. Atypical androgen receptor in the human melanoma cell line IIB-MEL-J. , 1995, Pigment cell research.
[89] Michael S. Pepper,et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth , 1994, Nature.
[90] F. Rampen. Sex Differences in Survival from Cutaneous Melanoma , 1984, International journal of dermatology.
[91] J. Mulder,et al. MALIGNANT MELANOMA: AN ANDROGEN-DEPENDENT TUMOUR? , 1980, The Lancet.
[92] W. McCarthy,et al. Endocrine influences on survival from malignant melanoma , 1978, Cancer.
[93] L. White. Studies on Melanoma , 1959 .